Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 11

Next Previous
Drug Profile

TT 11

Alternative Names: ATLCAR.CD30; CAR.CD30 T cells; CD30 CAR-T; CD30-directed genetically modified autologous T-cell therapy - Tessa Therapeutics; CD30.CAR-T; TT-11; TT11 CD30 CAR T

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine; University of North Carolina
  • Developer Tessa Therapeutics; University of North Carolina
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Germ cell cancer; Hodgkin's disease
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Hodgkin's-disease(Combination therapy, In adolescents, Recurrent, Second-line therapy or greater, In adults) in USA (Parenteral, Infusion)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Second-line therapy or greater, In adults) in USA (Parenteral, Infusion)
  • 16 Jun 2023 Adverse event and efficacy data from a phase I ACTION trial in Hodgkin's disease released by Tessa Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top